Methods for preventing neural tissue damage and for the treatment of alphasynuclein diseases

Details for Australian Patent Application No. 2001271865 (hide)

Owner Panacea Pharmaceuticals, Inc.

Inventors Lebowitz, Michael S.; Wolozin, Benjamin; Ostretova-Golts, Natalie

Agent Freehills

Pub. Number AU-B-2001271865

PCT Pub. Number WO02/04482

Priority 60279199 28.03.01 US; 60217319 07.07.00 US

Filing date 6 July 2001

Wipo publication date 21 January 2002

Acceptance publication date 25 May 2006

International Classifications

C07K 1/00 (2006.01) General processes for the preparation of peptides

C07K 7/06 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

C07K 16/18 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material from animals or humans

G01N 33/68 (2006.01) Investigating or analysing materials by specific methods not covered by groups - involving proteins, peptides or amino acids

Event Publications

25 May 2006 Application Accepted

  Published as AU-B-2001271865

7 December 2006 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 30 Jun 2006

14 December 2006 Standard Patent Sealed

3 February 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2001271866

2001271864